Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 10/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.70 |
| ▸ | GLA | P06280 | 1/20 | 0.70 |
| ▸ | CASP6 | P55212 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18339287 | 0.98 | HCAR3 (0.97) | HCAR3KDM4EGLACASP6TSHR | |
| SCHEMBL5326555 | 0.87 | HCAR3 (0.77) | HCAR3KDM4EGLACASP6TSHR | |
| SCHEMBL11697178 | 0.85 | HCAR3 (0.74) | HCAR3KDM4EGLACASP6TSHR | |
| SCHEMBL30503507 | 0.85 | HCAR3 (0.74) | HCAR3KDM4EGLALMNAALDH1A1 | |
| SCHEMBL10692442 | 0.84 | KDM4E (0.76) | HCAR3KDM4EGLALMNAALDH1A1 | |
| SCHEMBL1110902 | 0.83 | HCAR3 (0.70) | HCAR3KDM4EGLALMNAALDH1A1 | |
| SCHEMBL10502222 | 0.83 | HCAR3 (1.00) | HCAR3KDM4EGLACASP6TSHR | |
| SCHEMBL9632337 | 0.81 | HCAR3 (0.68) | HCAR3KDM4EGLACASP6TSHR | |
| SCHEMBL4299481 | 0.81 | HCAR3 (0.68) | HCAR3KDM4EGLALMNAALDH1A1 | |
| SCHEMBL4435755 | 0.80 | HCAR3 (0.67) | HCAR3KDM4EGLALMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12569566-B2 | Compositions containing, methods and uses of antibody-TLR agonist conjugates | AMBRX, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| CN-119455004-A | Compositions, methods and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-119455003-A | Compositions, methods and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-113660957-B | Compositions, methods and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20240027902-A1 | CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2024-01-25 | — | — | US | disclosed |
| US-20230359119-A1 | RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-11-09 | — | — | US | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230305393-A1 | RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-09-28 | — | — | US | disclosed |
| US-20230305394-A1 | RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-09-28 | — | — | US | disclosed |
| WO-2009043889-A2 | OXADIAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009043889-A2 | OXADIAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2009-04-09 | — | — | WO | disclosed |
| CN-101235244-A | Dazzling-proof hard coating material and high hardness hard coating film using same | DONGWOO FINE CHEM CO LTD (KR) | 2008-08-06 | — | — | CN | disclosed |
| EP-0685470-B1 | Benzene derivatives and pharmaceutical composition | KUREHA CHEMICAL IND CO LTD (JP) | 2002-09-11 | — | — | EP | disclosed |
| EP-0807628-B1 | Aromatic compound and pharmaceutical composition | KUREHA CHEMICAL IND CO LTD (JP) | 2000-12-20 | — | — | EP | disclosed |
| EP-0807628-A1 | Aromatic compound and pharmaceutical composition | Kureha Chemical Industry Co., Ltd. (JP) | 1997-11-19 | — | — | EP | disclosed |
| EP-0685470-A2 | Benzene derivatives and pharmaceutical composition | Kureha Chemical Industry Co., Ltd. (JP) | 1995-12-06 | — | — | EP | disclosed |
| EP-0170069-B1 | HAIR-DYEING COMPOSITIONS | Henkel Kommanditgesellschaft auf Aktien (DE) | 1989-10-11 | — | — | EP | disclosed |
| US-4619666-A | Hair dyes containing amino-nitrobenzoic acid or amino-nitrobenzene sulfonic acids as substantive dyes | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1986-10-28 | — | — | US | disclosed |
| EP-0170069-A1 | Hair-dyeing compositions | Henkel Kommanditgesellschaft auf Aktien (DE) | 1986-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | TLR3, TLR1, TLR9 | HCAR3 69/4885KDM4E 3476/4885GLA 3363/4885 |
| US-12569566-B2 | Compositions containing, methods and uses of antibody-TLR agonist conjugates | TLR3, TLR2, TLR1 | HCAR3 296/4885KDM4E 125/4885GLA 4009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.